Key Points
Nov 27 (Reuters) - Sanofi (SASY.PA) plans to file for U.S. approval of wider use of its anti-inflammatory drug Dupixent against "smoker's lung", also known as COPD, after a second large trial showed significant benefits...
Use in COPD, short for chronic obstructive pulmonary disease, could add billions to the French drugmaker's growth prospects but the trial success also underscores a heavy reliance on its bestselling exzema and asthma drug Dupixent...
Sanofi, which is collaborating on the drug with Regeneron (REGN.O), said in a statement on Monday that a second Dupixent phase 3 COPD trial showed that the drug reduced exacerbations of the disease by 34%...
